MAIA BIOTECHNOLOGY INC (MAIA) Stock News

NYSEARCA:MAIA - US5526411021 - Common Stock

1.58 USD

0 (0%)

Last: 8/25/2025, 8:04:02 PM

1.58 USD

0 (0%)

After Hours: 8/25/2025, 8:04:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MAIA Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy

a month ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

a month ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

4 months ago - By: Zacks Investment Research - Mentions: OCX BYRN

Best Momentum Stocks to Buy for May 6th

4 months ago - By: Zacks Investment Research - Mentions: BBVA HMY OCX BYRN

New Strong Buy Stocks for May 6th

2 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

2 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

2 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

2 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

3 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology to Present at BIO International Convention 2025

3 months ago - By: Benzinga - Mentions: REGN

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

3 months ago - By: MAIA Biotechnology

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

3 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

3 months ago - By: Yahoo Finance - Mentions: ETWO MS USB ABT ...

WiseTech Acquires E2open Parent Holdings, Inc. (ETWO) in $2.1 Billion Software Deal

3 months ago - By: Yahoo Finance - Mentions: USB ABT PSTG MEC ...

MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial

3 months ago - By: Yahoo Finance - Mentions: ALUR BIIB HOLX DUOL ...

Allurion Technologies Inc. (ALUR) Returns to France with 12.2% Weight Loss, 6.6% Muscle Gain Results

3 months ago - By: Yahoo Finance - Mentions: RDW PSTG MEC USB ...

Why Redwire Stock Triumphed on Tuesday

3 months ago - By: Yahoo Finance - Mentions: VZ USB BIIB GM ...

New XRP ETF is under official SEC review

3 months ago - By: MAIA Biotechnology, Inc.

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

3 months ago - By: Yahoo Finance - Mentions: WRBY HD TREX BIIB ...

Loop Capital Maintains Buy Rating on Warby Parker (WRBY) Stock

3 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

3 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Director Participation in Recent Private Placement

4 months ago - By: MAIA Biotechnology, Inc.

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

4 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces $1.08 Million Private Placement

5 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

5 months ago - By: Yahoo Finance - Mentions: ALIT AAPL CLF TSLA

Is Alight, Inc. (ALIT) About to Explode?

5 months ago - By: Yahoo Finance - Mentions: HRL KHC AVGO IBM ...

Best gold ETFs: Top funds for investing in gold

5 months ago - By: Zacks Investment Research

MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know

5 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

5 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

5 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

6 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

6 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

6 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

6 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Private Placement of $2,715,000

7 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

8 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology to Present at Biotech Showcase 2025

8 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications

8 months ago - By: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings